[{"address1": "9350 Kirby Drive", "address2": "Suite 300", "city": "Houston", "state": "TX", "zip": "77054", "country": "United States", "phone": "713 400 6400", "website": "https://markertherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Juan F. Vera M.D.", "age": 43, "title": "Co-Founder, CEO, President, Treasurer, Secretary & Director", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 399251, "exercisedValue": 0, "unexercisedValue": 39127}, {"maxAge": 1, "name": "Ms. Elizabeth  Donnelly", "title": "Director of Administration", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Maria-Bernadette  Madel", "age": 33, "title": "Director of Corporate Operations & External Communications", "yearBorn": 1990, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Cheung", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Monic  Stuart M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Patricia  Allison", "title": "Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary  Newman Ph.D.", "age": 64, "title": "Head of Regulatory Affairs", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Z. Florkiewicz Sr.", "title": "Senior Director of Molecular Biology & Virology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.71, "open": 2.76, "dayLow": 2.57, "dayHigh": 2.76, "regularMarketPreviousClose": 2.71, "regularMarketOpen": 2.76, "regularMarketDayLow": 2.57, "regularMarketDayHigh": 2.76, "beta": 1.553, "forwardPE": -1.7739725, "volume": 13206, "regularMarketVolume": 13206, "averageVolume": 26384, "averageVolume10days": 21480, "averageDailyVolume10Day": 21480, "bid": 1.97, "ask": 3.34, "bidSize": 100, "askSize": 200, "marketCap": 24537400, "fiftyTwoWeekLow": 2.4, "fiftyTwoWeekHigh": 6.16, "priceToSalesTrailing12Months": 6.582918, "fiftyDayAverage": 3.504, "twoHundredDayAverage": 4.18575, "currency": "USD", "enterpriseValue": 15309316, "profitMargins": -2.78222, "floatShares": 6762778, "sharesOutstanding": 8922700, "sharesShort": 64756, "sharesShortPriorMonth": 81052, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0073, "heldPercentInsiders": 0.12199, "heldPercentInstitutions": 0.22624001, "shortRatio": 2.14, "shortPercentOfFloat": 0.01, "impliedSharesOutstanding": 9473900, "bookValue": 1.087, "priceToBook": 2.3827045, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -10307587, "trailingEps": -1.15, "forwardEps": -1.46, "lastSplitFactor": "1:10", "lastSplitDate": 1674777600, "enterpriseToRevenue": 4.107, "52WeekChange": -0.31842107, "SandP52WeekChange": 0.34083736, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MRKR", "underlyingSymbol": "MRKR", "shortName": "Marker Therapeutics, Inc.", "longName": "Marker Therapeutics, Inc.", "firstTradeDateEpochUtc": 1026826200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f52316f7-d523-378a-bebe-a89c89d1c289", "messageBoardId": "finmb_1725474", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.59, "targetHighPrice": 12.5, "targetLowPrice": 11.0, "targetMeanPrice": 11.75, "targetMedianPrice": 11.75, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 7800464, "totalCashPerShare": 0.874, "quickRatio": 5.218, "currentRatio": 5.92, "totalRevenue": 3727435, "revenuePerShare": 0.42, "returnOnAssets": -0.40866002, "returnOnEquity": -0.71736, "freeCashflow": -7401172, "operatingCashflow": -10899731, "revenueGrowth": 0.533, "grossMargins": -1.56819, "operatingMargins": -1.97399, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-03"}]